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TECHNICAL NOTE
Noninvasive monitoring of renal transplant function by analysis
of beta2-microglobulin
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Medicine, The University of Texas Health Science Center at Dallas, The Southwestern Medical School, Dallas, Texas
Beta2-microglobulin (2M) is a low molecular weight (11,800
daltons) globular protein detected on the cell membrane of all
nucleated cells, including lymphocytes, where it is associated
with the glycoproteins of the major histocompatibility complex.
With a small sized Stokes radius, 16 A, and a sieving coefficient
of 0.7 to 1.0, 132M diffuses freely between intra- and extravascu-
lar space and is freely filtered through the glomerular basement
membrane, then reabsorbed (99.9%) and degraded by the
proximal tubular cells. The kidney, the major site of the
catabolism of /32M [1, 21, can extract and metabolize f32M even
in the absence of glomerular filtration [3, 4]. Under normal
circumstances, cellular synthesis, release, and catabolism of
this protein varies little in an individual. Although certain
inflammatory, immunologic, and neoplastic disorders can pro-
duce elevated serum levels in patients with normal renal
function, the usual cause of an elevation in serum beta2-
microglobulin (sI32M) is renal insufficiency. Because of these
properties, /32M is an excellent indicator of GFR [1]. Moreover,
in patients with recent kidney allografts who pass scanty
amounts of urine, continued clearance of /32M from the plasma
may be taken as evidence of graft viability [3, 4]. These
properties permit an analysis of the utility of sJ32M measure-
ments as a noninvasive laboratory assessment of renal trans-
plant status. At present, serum creatinine (sCr) is the standard,
noninvasive test available to evaluate renal function. However,
creatinine values can lag behind the histologic changes ob-
served in the rejection process and are of no use during
hemodialysis or in the presence of postsurgical acute renal
failure. The purpose, then, of this study was to explore the
relationship between sCr and 132M serum concentrations and to
evaluate the utility of monitoring transplant function with s/32M.
We found a strong correlation between f32M serum concentra-
tion and sCr, that a rise in s2M heralded the diagnosis of
transplant rejection, and that continued clearance of s2M in
the absence of excretory renal function supported a diagnosis of
postsurgical acute renal failure.
Methods. The patient population consisted of 70 cadaveric
and 23 living related donor renal transplant recipients who were
transplanted by the Parkiand Memorial Hospital, Southwestern
Medical School transplant team, from May 1980 through Janu-
ary 1982. Material for study was available for 90 rejection
episodes and 30 periods of postoperative acute renal failure.
Serum creatinine and s/32M concentrations were determined
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prior to the transplant and daily during the immediate post-
transplant hospital course.
Criteria utilized to establish a diagnosis of rejection included:
(1) the presence of diminished renal function unattributable to
mechanical problems or volume depletion in a previously
functioning transplant. Tangible evidence of such a diminished
function included a rise in sCr of> 0.2 mg/dl, a decrement in
GFR (as determined by clearance of '251-sodium iodothalamate)
of 10 ml/min and/or a 40% fall of urinary output; (2) increased
proteinuria; (3) fever unexplained by infection or atelectasis;
and (4) "graft" tenderness.
In all patients when rejection was diagnosed, a serum creati-
nine elevation of > 0.2 mg/dl was present along with, a
diminution in clearance substantiated by GFR measurement in
31 patients. Seventy-two patients had the clinical triad of graft
swelling, graft tenderness, and fever at the time renal function
declined. In 90 patients rejection was confirmed by arteriogra-
phy (vascular pruning, stretching, swelling of the kidney,
diminished cortical perfusion), renal biopsy (lymphocytic infil-
trate, interstitial edema), and/or DPT-technetium nuclide scan-
ing (diminished glomerular phase of nuclide excretion).
Acute renal failure was defined as the failure to observe
effective renal clearance postoperatively in the absence of
clinical rejection or mechanical impediment to renal function
and was confirmed in selected cases by renal biopsy. Postoper-
ative complications developed in five of the 93 patients. Two
patients exhibited a clinical syndrome consistent with cytomeg-
alovirus infection, with fever and a rise in CMV antibody
titer. Both patients became ill in the midst or immediately
following bolus steroid therapy after a diagnosis of rejection had
been confirmed and corroborated by s2M elevations. One
patient had herpes simplex of the oral pharynx which did not
effect sf32M concentrations. Listeria sepsis was seen in one
transplant patient experiencing severe rejection and requiring
hemodialysis at a time beyond the survey of s/32M. One
postoperative obstruction required urologic drainage. This pa-
tient, excluded from the analysis of 90 rejections as defined
above, did have both s/32M and sCr.
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f32M serum concentration. Serum M was measured using a
solid-phase radioimmunoassay technique employing commer-
cially available reagents (Pharmacia Diagnostics. Piscataway,
New Jersey) and standard technique [6].
Creatinine concentration. Serum creatinine was determined
by measuring total photochromogcns by the Technicon
autoanalyzer.
Results. The first task in a study detailing the utility of a
noninvasive monitoring technique is to establish basal fluctua-
tions in the variable under study. Prior to transplant, we found
that the mean sf2M concentration of dialyzed. uremic patients
---
was 34 14.1 mg/liter. In contrast, the mean s2M value in
patients with clinically successful allografts (glomerular clear-
ance  50 mI/mm) was 2.19 mg/liter. In these stable transplant
patients with good function (N = 7). the mean daily variation in
sf37M concentration was 0.06 0.08 mg/liter with mean change
no greater than 0.2 mg/liter in any one patient. Therefore, a
significant elevation was defined as twice the maximum varia-
tion observed in our stable group, or 0.4 mg/liter elevation in a
previously stable patient with good functioning kidneys (Table
1).
Our data permitted analysis of the relationship between the
s2M level and GFR as estimated by daily measurements of
sCr. We had available 1 .753 simultaneous sCr and s,M levels
for analysis, There was a highly significant relationship between
these two variables (y = I .65x + 1.88. r = 0.648: P < 0.0001)
(Fig. 1). One can conclude from this observation that there is a
biologically important relationship between renal function and
s7M levels and that sf37M should he a useful measurement in
estimating renal function.
Having established baseline characteristics of sf32M measure-
ments, we analyzed prospectively the utility of this measure-
ment in monitoring renal transplant function. First, we exam-
ined its utility to predict immunologic rejection. In the 90
rejection episodes available for analysis. s[3M concentration
was elevated significantly ( 0.4 mg/liter) at least I day prior to
an elevation of sCr in 49% (44 out of 90) of the patients. A
simultaneous rise in both sfM and sCr occurred in an addition-
al 42% (38 out of 90) with a mean elevation of 6.13 mg/liter (Fig.
2). A representative rejection episode in which sfJ2M increased
significantly prior to a rise in sCr raising the suspicion of the
diagnosis of rejection is illustrated in Figure 3. Eight patients
were considered to have transplant rejection in the absence of a
significant increase in s/32M concentration. We calculated the
sensitivity of the s[32M measurement to be 91% with a probabili-
ty of a false negative of 0.09. Noteworthy. sM did increase
significantly in those eight patients 24 to 48 hr later. On the
other hand. s2M was elevated in four patients after stable
levels had been reabsorbed without other evidence of rejection
revealing a specificity of the s2M measurement of 99% and the
probability of false positive at 0.01. From these data one can
conclude that a significant elevation in the s2M measurement
Table I. Quantitative relationships of heta-microglohulin in serum
used to monitor transplant patients
Normal range I I to 2.4 mg/liter
Mean daily variation in seven
stable patients 0.1)6 mg/liter
largest single change in stable
patients 0.2 mg/liter
Pretransplant uremic range 20.4 to 48.4 mg/liter
(34 it 14.1)
Elevation when rejection diag-
nosed 6. 3 mg/liter
range, 0.4 to 33.6)
False negatives
_______42%j Same day
Related I
to diagnosis I Day prior
of rejection
by serum
creatinine Within 1 day
L I I
y 1.65x I- 1.88
N 1753
r 0.648
P <0.0001
Rejections
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Fig. 2. Assessment of rejection by serum hera—microglobu/in analysis
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Fig. 1. The re/ationshi, between serum creauinine and serum heta-
microg/ohu/in. the regression line is drawn as the best fit through 1.753
sets of data with high confidence (P 0.0001). The upper arid lower
boundaries represent the 959i confidence limits of this relationship.
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Fig. 3. Post-transplant course in a representative patient. Note that
the s/32M rose significantly between post-transplant days 24 to 25 and
rises steeply to peak on day 27. Symbols are: 0—0, serum creatinine;
I—S 132 serum creatinine.
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Fig. 5. Post-transplant course in a representative patient with postsur-
gical acute renal failure. Note the persistent fall in sp2M from the first
postsurgical day while serum creatinine was useless diagnostically.
Symbols are: 0—0, serum creatinine; •—•, f3 serum concentration.
no cases in these 30 patients in which the sJ32M levels signifi-
cantly increased over the pretransplant level. Two patients
were observed with nonviable kidneys removed at days 30 and
33. In these two patients s/32M remained elevated above 10 mgI
liters throughout the entire hospital course. A representative
course of post-transplant acute renal failure in which s/32M
declined prior to sCr is presented in Figure 5.
Discussion. Monitoring renal allograft function using the
measurement of s2M concentration has been enthusiastically
endorsed by investigators analyzing several small patient popu-
lations [10—18]. Each of these limited series has found that sf32M
concentration frequently rises prior to other noninvasive evi-
dence of acute rejection and may fall before renal function is
established in postsurgical acute renal failure. Several unique
features of our study offer important advantages over the
previously published series. Firstly, pains were taken to deter-
mine baseline characteristics of sf32M levels. We established
mean concentrations in uremic patients as well as in stable
transplanted subjects. Importantly, the day-to-day fluctuations
in the technique of measuring sf32M were established in our
control group of stable transplant patients with good renal
function. From this group we determined that a clinically
significant change in concentration of s13,M was 0.4 mg/liter.
Secondly, we elected to sample s/32M levels on a daily basis
rather than "at regular intervals." Such frequent sampling gives
the clinician the full benefit of early increases in sf32M in
rejection and permits the investigator to analyze the incidence
of false positives and negatives. Thirdly, our study provides
data gleaned from a large patient population (93) using this
means of transplant function assessment. Our extensive study
of frequently analyzed patients confirms the impression of
previous studies. In our hands sf32M elevations up to 48 hr prior
to a rise in sCr were accurate in predicting or diagnosing
rejection in 91% of all patients. We could not, however, confirm
the observation of Schweizer et al [14] who felt that in certain
cases a diagnosis of rejection based on an elevation of s/32M as
much as 5 days prior to rises in sCr was possible. We conclude
from our study that sf32M is a useful adjunctive technique for
confirming the diagnosis of rejection. Moreover, a significant
Fig. 4. Serum f32-microglobulin levels in patients with postsurgical
acute renal failure. This complication was experienced by 32% (30 out
of 93) of our study group. In 19 patients (63%) sf32M continued to fall
prior to sCr indicating tissue viability and supporting the clinical
suspicion of acute renal failure.
is excellent corroborative evidence for the diagnosis of rejec-
tion. Moreover, an elevation of s/32M of 0.4 mg/liter or greater
after stable serum levels had been reabsorbed without a con-
comitant increase in sCr should raise the clinical suspicion of
rejection.
Because continued clearance of s2M has been observed in
the absence of renal function [3, 4], it has been suggested that
the s132M measurement may predict transplant viability. Hence
sf32M measurements may be helpful in differentiating irrevers-
ible rejection from reversible acute renal failure in the immedi-
ate postsurgical period of oliguria. We observed 30 patients
(32%) in our group who had "low output" acute renal failure
following surgery. Serum /32M levels continued to decline from
the pretranspiant level prior to a fall in sCr in 19 patients (63%)
indicating tissue viability and supporting the diagnosis of
uncomplicated acute renal failure. In the remaining patients
both sf32M and sCr remained elevated and varied with hemodi-
alysis and were of no use diagnostically (Fig. 4). We observed
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elevation in the s/32M level of  0.4 mg/liter in a patient with
stable function should be a warning to the clinician to observe
carefully for subtle signs of the onset of clinical rejection. The
data in 30 patients in whom acute renal failure was present
postsurgically allowed our study to confirm the original obser-
vation of Bernier and Post [iLl who demonstrated in 1973
continued clearance of sf32M in eight patients in the face of
initial transplant oliguria; this finding was suggested by other
studies as well [3, 4, 141. We conclude from our data that the
continued clearance of sf32M in the face of transplant oliguria
implies the presence of a viable allograft. Such a finding allows
the clinician to be confident in his diagnosis of acute renal
failure. Such confidence might allow the clinician to forego the
institution of a more invasive test to insure transplant viability.
In summary, our study of serum levels of 2M reveals a
highly significant correlation with sCr and documents that a 
0.4 mg/liter change in s/32M is both significant and sensitive in
monitoring renal transplant function. Daily measurement of
sf32M is a very effective technique in corroborating the diagno-
sis of transplant rejection and in supporting the diagnosis of
potentially reversible post-transplant acute renal failure.
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